Liquid Biopsy in Leukemia: Promise and Limits

What does the term mean?

The National Cancer Institute describes liquid biopsy as testing blood or another body fluid for cancer cells or material released from them. Cell-free DNA includes DNA fragments in the fluid; the tumour-derived portion is commonly called circulating tumour DNA. These terms are related but not interchangeable. ^[1]

A blood draw is minimally invasive. Calling it completely non-invasive, or describing it as a replacement for every tissue or marrow assessment, overstates what the term establishes.

A defined example from AML research

Hupe and colleagues evaluated plasma cell-free DNA in 15 patients with isolated extramedullary AML manifestations. They compared molecular findings across plasma, marrow and peripheral-blood cell samples. The study reported that plasma DNA captured relevant mutations in that specific setting. Its small, selected cohort does not establish performance across all people with leukemia. ^[2]

This is a useful research example because it asks where different sample types may provide complementary information. It should not be generalized into a universal screening claim.

Interpretation depends on method and context

MRD assessment has technical and reporting requirements. European LeukemiaNet's foundational AML consensus emphasizes that technique, specimen and timing matter when interpreting results. ^[3]

For readers comparing studies, ask whether the same biological target and reference standard were used. Also distinguish detecting a molecular signal from proving that a change in management improves outcomes.

Where AI fits in the discussion

Our view is that computational methods should be evaluated against a defined task and dataset, rather than assumed to improve every assay. Combining molecular and imaging information is a research question that needs its own evidence.

CellSight follows these developments as external scientific context. This article does not claim that its working first version performs liquid biopsy or provides molecular diagnostic testing.